Karyopharm Therapeutics Inc (NASDAQ:KPTI) shares were up 5% during mid-day trading on Monday . The stock traded as high as $9.15 and last traded at $8.99. Approximately 827,229 shares traded hands during trading, an increase of 44% from the average daily volume of 576,319 shares. The stock had previously closed at $8.56.
A number of analysts recently issued reports on KPTI shares. Zacks Investment Research raised Karyopharm Therapeutics from a “hold” rating to a “buy” rating and set a $11.00 target price for the company in a research report on Thursday, January 10th. HC Wainwright reissued a “buy” rating on shares of Karyopharm Therapeutics in a research report on Monday, December 3rd. B. Riley started coverage on Karyopharm Therapeutics in a research report on Friday, November 30th. They issued a “buy” rating and a $23.00 target price for the company. ValuEngine cut Karyopharm Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, October 11th. Finally, BidaskClub raised Karyopharm Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, November 8th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and ten have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $21.90.
The company has a market cap of $542.75 million, a price-to-earnings ratio of -3.21 and a beta of 3.42.
Karyopharm Therapeutics (NASDAQ:KPTI) last released its quarterly earnings data on Thursday, November 8th. The company reported ($0.79) earnings per share for the quarter, beating the consensus estimate of ($0.88) by $0.09. Karyopharm Therapeutics had a negative return on equity of 104.50% and a negative net margin of 502.90%. The firm had revenue of $0.24 million during the quarter, compared to the consensus estimate of $1.21 million. As a group, research analysts predict that Karyopharm Therapeutics Inc will post -2.97 EPS for the current fiscal year.
In other Karyopharm Therapeutics news, insider Sharon Shacham sold 12,500 shares of the firm’s stock in a transaction on Friday, December 7th. The stock was sold at an average price of $10.11, for a total transaction of $126,375.00. Following the completion of the transaction, the insider now owns 726,010 shares of the company’s stock, valued at $7,339,961.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Michael Kauffman sold 9,600 shares of the firm’s stock in a transaction on Monday, November 26th. The stock was sold at an average price of $11.00, for a total value of $105,600.00. Following the transaction, the chief executive officer now directly owns 521,743 shares of the company’s stock, valued at approximately $5,739,173. The disclosure for this sale can be found here. Insiders sold a total of 35,000 shares of company stock valued at $364,306 over the last ninety days. 13.26% of the stock is currently owned by company insiders.
Several hedge funds have recently bought and sold shares of KPTI. Birchview Capital LP raised its stake in Karyopharm Therapeutics by 40.0% during the 4th quarter. Birchview Capital LP now owns 70,000 shares of the company’s stock valued at $656,000 after purchasing an additional 20,000 shares during the period. Virtus ETF Advisers LLC raised its stake in Karyopharm Therapeutics by 17.1% during the 4th quarter. Virtus ETF Advisers LLC now owns 30,726 shares of the company’s stock valued at $288,000 after purchasing an additional 4,488 shares during the period. Emerald Mutual Fund Advisers Trust raised its stake in Karyopharm Therapeutics by 112.2% during the 4th quarter. Emerald Mutual Fund Advisers Trust now owns 1,373,437 shares of the company’s stock valued at $12,869,000 after purchasing an additional 726,130 shares during the period. Rhumbline Advisers grew its holdings in shares of Karyopharm Therapeutics by 119.9% during the 4th quarter. Rhumbline Advisers now owns 93,819 shares of the company’s stock valued at $879,000 after acquiring an additional 51,163 shares in the last quarter. Finally, Emerald Advisers LLC grew its holdings in shares of Karyopharm Therapeutics by 109.8% during the 4th quarter. Emerald Advisers LLC now owns 1,456,473 shares of the company’s stock valued at $13,647,000 after acquiring an additional 762,405 shares in the last quarter. Institutional investors and hedge funds own 72.65% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Karyopharm Therapeutics (KPTI) Trading Up 5%” was originally published by Enterprise Leader and is owned by of Enterprise Leader. If you are viewing this story on another domain, it was stolen and reposted in violation of US & international copyright and trademark law. The legal version of this story can be read at https://theenterpriseleader.com/2019/02/06/karyopharm-therapeutics-kpti-trading-up-5.html.
Karyopharm Therapeutics Company Profile (NASDAQ:KPTI)
Karyopharm Therapeutics Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor(KPT-330), which is in Phase 2b clinical study in treatments of refractory multiple myeloma; Phase 1b/2 clinical study in combination with backbone treatments for multiple myeloma patients; Phase 2b clinical study in diffuse large B-cell lymphoma; Phase 3 clinical trial in combination with Velcade (bortezomib) and dexamethasone for multiple myeloma patients; and Phase 2/3 clinical study in liposarcoma.
Featured Article: 12b-1 Fees
Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.